Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;33(11):2375-2381.
doi: 10.1111/jce.15670. Epub 2022 Oct 2.

Sacubitril/valsartan: An antiarrhythmic drug?

Elaine Huang  1 , Michael L Bernard  2 , A Elise Hiltbold  2 , Sammy Khatib  2 , Glenn M Polin  2 , Paul A Rogers  2 , Paari Dominic  3 , Daniel P Morin  2   4
Affiliations
Review

Sacubitril/valsartan: An antiarrhythmic drug?

Elaine Huang et al. J Cardiovasc Electrophysiol. 2022 Nov.

Abstract

Introduction: Heart failure (HF) is a major cause of morbidity and mortality, with nearly half of all HF-related deaths resulting from sudden cardiac death (SCD), most often from an arrhythmic event. The pathophysiologic changes that occur in response to the hemodynamic stress of HF may lead to increased arrhythmogenesis. Theoretically, medications that block these arrhythmogenic substrates would decrease the risk of SCD. The combined angiotensin receptor and neprilysin inhibitor (ARNi; tradename Entresto) is the newest commercially available medication for the treatment of heart failure.

Methods and results: We reviewed and synthesized the available literature regarding sacubitril/valsartan and its effects on cardiac rhythm. ARNi has been shown to decrease cardiovascular mortality and hospitalization in patients with HF with reduced ejection fraction (HFrEF). Emerging evidence suggests that ARNi also may play a role in reducing arrhythmogenesis and thereby SCD.

Conclusion: This review summarizes the current data regarding this ARNi and its potential antiarrhythmic effects.

Keywords: ARNi; Entresto; arrhythmia; heart failure; sacubitril; sudden cardiac death; valsartan.

PubMed Disclaimer

References

REFERENCES

    1. Heart Failure | cdc.gov. Heart Failure. Accessed January 25, 2022, from https://www.cdc.gov/heartdisease/heart_failure.htm
    1. Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014-2020). Pharmacoeconomics. 2020;38:1219-1236.
    1. Agency for Healthcare Research and Quality. Most Common Diagnoses in Hospital Inpatient Stays - HCUP Fast Stats. Accessed January 25, 2022. from https://www.hcup-us.ahrq.gov/faststats/NationalDiagnosesServlet
    1. Tomaselli GF, Zipes DP. What causes sudden death in heart failure. Circ Res. 2004;95:754-763.
    1. Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41-51.

MeSH terms